Safety Study of ORG 34517 for Major Depression With Psychotic Features

NCT00226278 | Completed Phase 2

• 1 other identifier: 28130
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Patients suffering from Major Depressive Disorder with Psychotic features who have received no changes in their medications in the previous two weeks will receive "usual" treatment of antidepressants, antipsychotics and/or mood stabilizers and adjunct therapy using ORG34517. The patient will be hospitalized for up to two weeks to monitor their medications and progress and will return to the site for periodic assessments.

Conditions

Major Depressive Disorder; Psychotic Disorders

Interventions

ORG 34517 DRUG

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• provide voluntary written informed consent for trial participation after the scope and nature of the investigation have been explained to them, and before starting any trial related activities
• be able to speak, read, understand, respond to questions and follow instructions in English
• have a DSM-IV severe depressive episode with psychotic features, as diagnosed by the MINI for single or recurrent episodes
• have a score on PANSS item "Delusions" AND/OR "Hallucinatory behavior" of at least 4 at screening and baseline
• have a PANSS Positive Scale score of at least 16 at screening and baseline
• have a total score of at least 18 on teh HAMD 17 item scale at Screening and Baseline
• be on a stable dose of usual treatment which has to consist of an anti-depressant, an antipsychotic, a mood stabilizer or any combination of these three drug classes
• be 18 up to and including 70 years of age at Screening
• must be willing to be hospitalized for at least 11 days from Screening onwards.

You may not qualify if:

• have any other psychiatric diagnosis except MDD
• have a lifetime psychiatric diagnosis of Bipolar Disorder I, schizophrenia or schizoaffective disorders
• are at significant risk of committing suicide
• are currently treated with carbamazepine or valproate
• are currently treated with midazolam
• have been treated with electroconvulsive therapy in the current episode
• are currently treated with more than one antidepressant
• are currently treated with more than one antipsychotic
• are currently treated with more than one mood stabilizer
• have usual treatment started or discontinued in the two weeks before randomization
• have a usual treatment dose change within the week prior to randomization
• have any clinically unstable or uncontrollable renal, hepatic, respiratory, haematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment efficacy
• have known hypersensitivity reactions to glucocorticoid antagonists
• have any clinically significant abnormal laboratory data
• have any untreated or uncompensated clinically significant endocrine disorder

Sponsors & Collaborators

• Weill Medical College of Cornell University: lead

Study Sites (1)

Weill Cornell Medical College/New York Presbyterian Hospital

New York, New York, 10021, United States

Location

MeSH Terms

Conditions

Depressive Disorder, Major; Psychotic Disorders

Interventions

Org 34517

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders

Study Officials

• James H Kocsis, MD

  Weill Medical College of Cornell University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 22, 2005
• First Posted: September 26, 2005
• Study Start: September 1, 2004
• Primary Completion: November 1, 2005
• Study Completion: November 1, 2005
• Last Updated: March 31, 2008

Record last verified: 2008-03

Locations

US (1)